Latest news with #N.G.VijayaGopal
India Gazette
2 days ago
- Health
- India Gazette
Government backs Indian Startup pioneering domestic stroke treatment technology
Mysuru (Karnataka) [India], June 2 (ANI): A breakthrough in India's medical technology landscape has emerged with government backing for S3V Vascular Technologies, a Mysuru-headquartered company developing indigenous stroke intervention devices. The Technology Development Board has greenlit financial assistance for what could become India's first locally-manufactured mechanical thrombectomy system. Addressing a Critical Healthcare Gap Stroke treatment in India faces significant challenges due to expensive imported medical devices. Current thrombectomy procedures--which involve removing blood clots from brain arteries--rely almost entirely on foreign-made equipment, creating cost barriers that prevent many patients from accessing life-saving care. The minimally invasive thrombectomy technique has revolutionised acute stroke treatment, offering superior results compared to traditional clot-dissolving medications when performed promptly. Despite its effectiveness, the procedure remains financially out of reach for numerous Indian patients due to import-dependent pricing. Manufacturing Initiative Takes Shape S3V Vascular Technologies plans to establish comprehensive production capabilities at Tamil Nadu's Medical Devices Park in Oragadam, situated near Sriperumbudur. This facility will create a complete range of specialised neurological intervention instruments, encompassing microcatheters, aspiration systems, precision guidewires, and clot-retrieval stents. Dr. N.G. Vijaya Gopal, the company's founder and managing director, emphasises their commitment to reducing import dependency across the entire supply chain, not merely final assembly. The organisation has already begun pursuing international certifications, including CE marking and FDA approval, targeting export markets spanning Asia, Latin America, Europe, and North America. Strategic Investment Partners The venture has secured support from notable Indian business leaders and investment firms. Larsen & Toubro's Chairman Emeritus A.M. Naik, MK Ventures' Madhusudan Kela, and Rare Enterprises CEO Utpal Sheth have all committed capital to the project. This high-profile investor participation signals growing confidence in India's deep technology and import-substitution healthcare opportunities. Market Potential and Access Challenges India's neurological intervention sector represents approximately $2 billion in market value, yet treatment availability remains concentrated in major urban centres. Rural areas and smaller cities face particular difficulties accessing advanced stroke care due to infrastructure limitations and specialist shortages. S3V aims to bridge this accessibility gap through hospital partnerships focused on simulation-based education programs for emerging neuro-interventionists and radiologists, potentially expanding treatment capacity nationwide. Government Alignment and Innovation Technology Development Board Secretary Rajesh Kumar Pathak highlighted the project's strategic importance, noting its alignment with India's goals to establish the country as a global centre for affordable, sophisticated medical technologies. He emphasised that domestic healthcare innovation represents a crucial component of national health security. The company has developed proprietary intellectual property, including novel clot retriever designs and specialised braid-over-coil aspiration catheter structures. These patented innovations focus on enhancing device safety and effectiveness in challenging clinical situations. Integration with National Health Programs S3V is exploring collaboration opportunities with government healthcare initiatives, particularly integration with Ayushman Bharat and similar national schemes. Successful implementation could dramatically reduce thrombectomy procedure costs while improving patient outcomes across thousands of cases annually. (ANI)
Hans India
4 days ago
- Health
- Hans India
Govt to aid development of India's 1st indigenous thrombectomy device for stroke care
New Delhi: In a significant boost to India's medtech innovation landscape, the Technology Development Board (TDB), under the Union Department of Science and Technology (DST), on Friday announced financial support to the development of India's first indigenous thrombectomy device for stroke care. The board sanctioned assistance to Mysuru-based S3V Vascular Technologies' pioneering neuro-intervention integrated manufacturing plant for the treatment of stroke, which sees nearly 1.5 million cases every year in the country. The project envisions the establishment of a state-of-the-art upstream integrated manufacturing facility at the Medical Devices Park, Oragadam in Chennai's Sriperumbudur. The plant will develop and manufacture advanced mechanical thrombectomy kits -- a life-saving intervention for patients suffering from acute ischemic stroke due to large vessel occlusion. Compared to conventional thrombolysis, thrombectomy offers significantly improved outcomes, reducing the risk of long-term paralysis and disability. "The TDB is proud to support S3V's vision of building India's first comprehensive neuro-intervention manufacturing ecosystem. This project reflects our continued commitment to making India a global hub for affordable, high-end medical technology -- especially in areas of critical public health needs like stroke care," TDB Secretary Rajesh Kumar Pathak said. "The company's focus on integrating these devices into Ayushman Bharat further aligns with the national goal of inclusive healthcare access," he added. The initiative will help replace expensive imported devices with high-quality, locally manufactured alternatives, enhancing both the affordability and accessibility of stroke care in India. "Our integrated manufacturing facility will not only reduce dependency on imports of the finished medical devices used in Mechanical Thrombectomy but also reduces India's dependency on import of the raw materials used in manufacturing of these critical complex lifesaving medical devices," S3V Vascular Technologies Managing Director, Dr N.G. Vijaya Gopal, said, while lauding the government for its support. Gopal said the company has already initiated the CE and the US FDA approval process for the devices to expand access to cutting-edge stroke care solutions across India, Asia, Latin America, Europe, and the US.
